cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.14272/mkzkxvuzvqmbss-wqlsenkssa-n.1
title: C13H14N2O3S
title: InChI=1S/C13H14N2O3S/c1-3-18-13-9(2)19-12(14-13)8-10-4-6-11(7-5-10)15(16)17/h4-9H,3H2,1-2H3/b12-8-

description: This is a physical chemical entity[CHEBI_24431] associated with a molecule[CHEBI_25367]. The molecule[CHEBI_25367] can be described by the following structural desciptors[cheminf_000085]: InChI descriptor[cheminf_000113]: InChI=1S/C13H14N2O3S/c1-3-18-13-9(2)19-12(14-13)8-10-4-6-11(7-5-10)15(16)17/h4-9H,3H2,1-2H3/b12-8-, and canonical SMILES descriptor[cheminf_000007]: CCOC1=N/C(=C/c2ccc(cc2)[N+](=O)[O-])/SC1C, and by the IUPAC name[cheminf_000107]: . The physical chemical entity[CHEBI_24431] has a component solvent[CHEBI_46787] which is described by the canonical SMILES descriptor[cheminf_000007]: The physical chemical entity[CHEBI_24431] has the following Sample ID as registered in the research data repository chemotion (www.chemotion-repository.net, https://doi.org/10.25504/FAIRsharing.iagXcR): CRS-36425 The physical chemical entity[CHEBI_24431] can be described by the physical descriptors [CHEMINF_000025]: Melting point descriptor[CHEMINF_000256]: 191.9 (°C) Boiling point descriptor[CHEMINF_000257]: Refractive index descriptor[CHEMINF_000253]: The physical chemical entity[CHEBI_24431] can be further described by the following assays[OBI:0000070][CHMO:0001133]: CHMO:0000630 | infrared absorption spectroscopy (IR) CHMO:0000796 | high-performance liquid chromatography-mass spectrometry (HPLC-MS) CHMO:0000593 | 1H nuclear magnetic resonance spectroscopy (1H NMR) CHMO:0000595 | 13C nuclear magnetic resonance spectroscopy (13C NMR) CHMO:0000596 | distortionless enhancement with polarization transfer (DEPT) The physical chemical entity[CHEBI_24431] was deposited to the Molecule Archive of the Karlsruhe Insitute of Technology (KIT) with the following Sample ID: Used ontologies: CHEBI - Chemical Entities of Biological Interest CHEMINF - chemical information ontology (information entities about chemical entities) CHMO - Chemical Methods Ontology OBI - Ontology for Biomedical Investigations
DOI: 10.14272/mkzkxvuzvqmbss-wqlsenkssa-n/chmo0000596
title: distortionless enhancement with polarization transfer (DEPT) ()
title: InChI=1S/C13H14N2O3S/c1-3-18-13-9(2)19-12(14-13)8-10-4-6-11(7-5-10)15(16)17/h4-9H,3H2,1-2H3/b12-8-

description: dataset for distortionless enhancement with polarization transfer (DEPT) 13C NMR (75 MHz, Chloroform-d [77.0 ppm], ppm) δ = 127.8, 124.0, 99.9, 41.7, 38.3, 19.6, 12.1.
DOI: 10.14272/mkzkxvuzvqmbss-wqlsenkssa-n/chmo0000630
title: infrared absorption spectroscopy (IR) ()
title: InChI=1S/C13H14N2O3S/c1-3-18-13-9(2)19-12(14-13)8-10-4-6-11(7-5-10)15(16)17/h4-9H,3H2,1-2H3/b12-8-

description: dataset for infrared absorption spectroscopy (IR) IR (ATR, ṽ) = 3109 (w), 2979 (w), 2933 (w), 2899 (w), 2872 (w), 1697 (vs), 1605 (m), 1572 (vs), 1500 (vs), 1461 (m), 1448 (m), 1413 (m), 1396 (s), 1324 (vs), 1280 (vs), 1245 (s), 1200 (vs), 1134 (s), 1122 (m), 1109 (vs), 1083 (s), 1066 (s), 1036 (m), 993 (m), 972 (m), 917 (w), 903 (w), 880 (w), 852 (vs), 815 (m), 804 (s), 793 (m), 748 (s), 741 (m), 728 (m), 715 (w), 691 (vs), 677 (s), 662 (m) cm–1.
DOI: 10.14272/mkzkxvuzvqmbss-wqlsenkssa-n/chmo0000796
title: high-performance liquid chromatography-mass spectrometry (HPLC-MS) ()
title: InChI=1S/C13H14N2O3S/c1-3-18-13-9(2)19-12(14-13)8-10-4-6-11(7-5-10)15(16)17/h4-9H,3H2,1-2H3/b12-8-

description: dataset for high-performance liquid chromatography-mass spectrometry (HPLC-MS) ESI (MS) m/z = 279.1 (100) [M+H]+, 301.1 (66) [M+Na]+.
DOI: 10.14272/mkzkxvuzvqmbss-wqlsenkssa-n/chmo0000593
title: 1H nuclear magnetic resonance spectroscopy (1H NMR) ()
title: InChI=1S/C13H14N2O3S/c1-3-18-13-9(2)19-12(14-13)8-10-4-6-11(7-5-10)15(16)17/h4-9H,3H2,1-2H3/b12-8-

description: dataset for 1H nuclear magnetic resonance spectroscopy (1H NMR) 1H NMR (300 MHz, CDCl3, ppm) δ = 8.24–8.13 (m, 2H), 7.54–7.45 (m, 2H), 6.05 (s, 1H), 4.08 (q, J = 7.1 Hz, 1H), 3.84 (qd, J = 7.3, 1.3 Hz, 2H), 1.66 (dd, J = 7.1, 1.2 Hz, 3H), 1.29 (td, J = 7.2, 1.1 Hz, 3H).
DOI: 10.14272/mkzkxvuzvqmbss-wqlsenkssa-n/chmo0000595
title: 13C nuclear magnetic resonance spectroscopy (13C NMR) ()
title: InChI=1S/C13H14N2O3S/c1-3-18-13-9(2)19-12(14-13)8-10-4-6-11(7-5-10)15(16)17/h4-9H,3H2,1-2H3/b12-8-

description: dataset for 13C nuclear magnetic resonance spectroscopy (13C NMR) 13C NMR (75 MHz, Chloroform-d [77.0 ppm], ppm) δ = 173.5, 145.0, 143.3, 140.8, 127.9 (2C), 124.1 (2C), 100.0, 41.8, 38.4, 19.7, 12.2.
DOI: 10.5281/zenodo.10032788
title: Stress shift in noun-verb conversion pairs_data
DOI: 10.5281/zenodo.10032789
title: Stress shift in noun-verb conversion pairs_data
DOI: 10.14272/jtnfrcmtcjszak-uhfffaoysa-n.1
title: C17H26N2OSSi
title: InChI=1S/C17H26N2OSSi/c1-12-16(20-22(5,6)17(2,3)4)19-15(21-12)11-13-7-9-14(18)10-8-13/h7-10H,11,18H2,1-6H3

description: This is a physical chemical entity[CHEBI_24431] associated with a molecule[CHEBI_25367]. The molecule[CHEBI_25367] can be described by the following structural desciptors[cheminf_000085]: InChI descriptor[cheminf_000113]: InChI=1S/C17H26N2OSSi/c1-12-16(20-22(5,6)17(2,3)4)19-15(21-12)11-13-7-9-14(18)10-8-13/h7-10H,11,18H2,1-6H3, and canonical SMILES descriptor[cheminf_000007]: Nc1ccc(cc1)Cc1nc(c(s1)C)O[Si](C(C)(C)C)(C)C, and by the IUPAC name[cheminf_000107]: . The physical chemical entity[CHEBI_24431] has a component solvent[CHEBI_46787] which is described by the canonical SMILES descriptor[cheminf_000007]: The physical chemical entity[CHEBI_24431] has the following Sample ID as registered in the research data repository chemotion (www.chemotion-repository.net, https://doi.org/10.25504/FAIRsharing.iagXcR): CRS-36414 The physical chemical entity[CHEBI_24431] can be described by the physical descriptors [CHEMINF_000025]: Melting point descriptor[CHEMINF_000256]: Boiling point descriptor[CHEMINF_000257]: Refractive index descriptor[CHEMINF_000253]: The physical chemical entity[CHEBI_24431] can be further described by the following assays[OBI:0000070][CHMO:0001133]: CHMO:0000593 | 1H nuclear magnetic resonance spectroscopy (1H NMR) CHMO:0000595 | 13C nuclear magnetic resonance spectroscopy (13C NMR) CHMO:0000630 | infrared absorption spectroscopy (IR) CHMO:0000470 | mass spectrometry (MS) The physical chemical entity[CHEBI_24431] was deposited to the Molecule Archive of the Karlsruhe Insitute of Technology (KIT) with the following Sample ID: Used ontologies: CHEBI - Chemical Entities of Biological Interest CHEMINF - chemical information ontology (information entities about chemical entities) CHMO - Chemical Methods Ontology OBI - Ontology for Biomedical Investigations
DOI: 10.14272/jtnfrcmtcjszak-uhfffaoysa-n/chmo0000593
title: 1H nuclear magnetic resonance spectroscopy (1H NMR) ()
title: InChI=1S/C17H26N2OSSi/c1-12-16(20-22(5,6)17(2,3)4)19-15(21-12)11-13-7-9-14(18)10-8-13/h7-10H,11,18H2,1-6H3

description: dataset for 1H nuclear magnetic resonance spectroscopy (1H NMR) 1H NMR (62 MHz, Chloroform-d, ppm) δ = 7.15–7.02 (m, 2H), 6.71–6.57 (m, 2H), 4.00 (s, 2H), 3.58 (s, 2H), 2.13 (s, 3H), 0.99 (s, 9H), 0.25 (s, 6H).
DOI: 10.14272/jtnfrcmtcjszak-uhfffaoysa-n/chmo0000470
title: mass spectrometry (MS) ()
title: InChI=1S/C17H26N2OSSi/c1-12-16(20-22(5,6)17(2,3)4)19-15(21-12)11-13-7-9-14(18)10-8-13/h7-10H,11,18H2,1-6H3

description: dataset for mass spectrometry (MS) MS (ESI) m/z = 335.1 [M+H]+.
DOI: 10.14272/jtnfrcmtcjszak-uhfffaoysa-n/chmo0000630
title: infrared absorption spectroscopy (IR) ()
title: InChI=1S/C17H26N2OSSi/c1-12-16(20-22(5,6)17(2,3)4)19-15(21-12)11-13-7-9-14(18)10-8-13/h7-10H,11,18H2,1-6H3

description: dataset for infrared absorption spectroscopy (IR) IR (ATR, ṽ) = 3454 (vw), 3359 (vw), 3221 (vw), 2953 (w), 2928 (w), 2896 (vw), 2857 (w), 1624 (w), 1561 (vs), 1516 (s), 1471 (w), 1463 (w), 1439 (w), 1425 (w), 1408 (w), 1383 (w), 1361 (w), 1323 (vs), 1279 (w), 1250 (m), 1227 (w), 1208 (w), 1179 (w), 1168 (w), 1134 (m), 1007 (w), 948 (m), 939 (w), 910 (w), 828 (vs), 817 (vs), 783 (vs), 748 (w), 738 (w), 726 (w), 686 (m), 667 (m) cm–1.
DOI: 10.14272/jtnfrcmtcjszak-uhfffaoysa-n/chmo0000595
title: 13C nuclear magnetic resonance spectroscopy (13C NMR) ()
title: InChI=1S/C17H26N2OSSi/c1-12-16(20-22(5,6)17(2,3)4)19-15(21-12)11-13-7-9-14(18)10-8-13/h7-10H,11,18H2,1-6H3

description: dataset for 13C nuclear magnetic resonance spectroscopy (13C NMR) 13C NMR (75 MHz, Chloroform-d [77.0 ppm], ppm) δ = 162.8, 155.6, 145.2, 130.1 (2C), 128.4, 115.5 (2C), 106.6, 39.3, 26.0 (3C), 18.3, 9.5, -4.1 (2C).
DOI: 10.14272/jlxpvwcvmwrpbl-uhfffaoysa-n.1
title: C17H24N2O3SSi
title: InChI=1S/C17H24N2O3SSi/c1-12-16(22-24(5,6)17(2,3)4)18-15(23-12)11-13-7-9-14(10-8-13)19(20)21/h7-10H,11H2,1-6H3

description: This is a physical chemical entity[CHEBI_24431] associated with a molecule[CHEBI_25367]. The molecule[CHEBI_25367] can be described by the following structural desciptors[cheminf_000085]: InChI descriptor[cheminf_000113]: InChI=1S/C17H24N2O3SSi/c1-12-16(22-24(5,6)17(2,3)4)18-15(23-12)11-13-7-9-14(10-8-13)19(20)21/h7-10H,11H2,1-6H3, and canonical SMILES descriptor[cheminf_000007]: Cc1sc(nc1O[Si](C(C)(C)C)(C)C)Cc1ccc(cc1)[N+](=O)[O-], and by the IUPAC name[cheminf_000107]: . The physical chemical entity[CHEBI_24431] has a component solvent[CHEBI_46787] which is described by the canonical SMILES descriptor[cheminf_000007]: The physical chemical entity[CHEBI_24431] has the following Sample ID as registered in the research data repository chemotion (www.chemotion-repository.net, https://doi.org/10.25504/FAIRsharing.iagXcR): CRS-36419 The physical chemical entity[CHEBI_24431] can be described by the physical descriptors [CHEMINF_000025]: Melting point descriptor[CHEMINF_000256]: 48.5 (°C) Boiling point descriptor[CHEMINF_000257]: Refractive index descriptor[CHEMINF_000253]: The physical chemical entity[CHEBI_24431] can be further described by the following assays[OBI:0000070][CHMO:0001133]: CHMO:0000630 | infrared absorption spectroscopy (IR) CHMO:0000796 | high-performance liquid chromatography-mass spectrometry (HPLC-MS) CHMO:0000593 | 1H nuclear magnetic resonance spectroscopy (1H NMR) CHMO:0000595 | 13C nuclear magnetic resonance spectroscopy (13C NMR) The physical chemical entity[CHEBI_24431] was deposited to the Molecule Archive of the Karlsruhe Insitute of Technology (KIT) with the following Sample ID: Used ontologies: CHEBI - Chemical Entities of Biological Interest CHEMINF - chemical information ontology (information entities about chemical entities) CHMO - Chemical Methods Ontology OBI - Ontology for Biomedical Investigations
DOI: 10.14272/jlxpvwcvmwrpbl-uhfffaoysa-n/chmo0000796
title: high-performance liquid chromatography-mass spectrometry (HPLC-MS) ()
title: InChI=1S/C17H24N2O3SSi/c1-12-16(22-24(5,6)17(2,3)4)18-15(23-12)11-13-7-9-14(10-8-13)19(20)21/h7-10H,11H2,1-6H3

description: dataset for high-performance liquid chromatography-mass spectrometry (HPLC-MS) MS (ESI) m/z = 387.1 [M+Na]+.
DOI: 10.14272/jlxpvwcvmwrpbl-uhfffaoysa-n/chmo0000595
title: 13C nuclear magnetic resonance spectroscopy (13C NMR) ()
title: InChI=1S/C17H24N2O3SSi/c1-12-16(22-24(5,6)17(2,3)4)18-15(23-12)11-13-7-9-14(10-8-13)19(20)21/h7-10H,11H2,1-6H3

description: dataset for 13C nuclear magnetic resonance spectroscopy (13C NMR) 13C NMR (75 MHz, Chloroform-d [77.0 ppm], ppm) δ = 158.4, 156.0, 147.0, 145.7, 129.9 (2C), 123.9 (2C), 107.4, 39.5, 25.9 (3C), 18.2, 9.5, -4.2 (2C).
DOI: 10.14272/jlxpvwcvmwrpbl-uhfffaoysa-n/chmo0000630
title: infrared absorption spectroscopy (IR) ()
title: InChI=1S/C17H24N2O3SSi/c1-12-16(22-24(5,6)17(2,3)4)18-15(23-12)11-13-7-9-14(10-8-13)19(20)21/h7-10H,11H2,1-6H3

description: dataset for infrared absorption spectroscopy (IR) IR (ATR, ṽ) = 2955 (w), 2928 (w), 2855 (w), 1605 (w), 1565 (vs), 1516 (vs), 1492 (w), 1470 (w), 1464 (w), 1385 (w), 1360 (w), 1342 (vs), 1332 (vs), 1297 (w), 1248 (s), 1203 (w), 1188 (w), 1172 (w), 1150 (m), 1129 (m), 1108 (m), 1014 (w), 945 (m), 865 (w), 843 (s), 830 (vs), 819 (vs), 784 (vs), 752 (m), 727 (w), 706 (vs), 687 (m), 673 (s) cm–1.
DOI: 10.14272/jlxpvwcvmwrpbl-uhfffaoysa-n/chmo0000593
title: 1H nuclear magnetic resonance spectroscopy (1H NMR) ()
title: InChI=1S/C17H24N2O3SSi/c1-12-16(22-24(5,6)17(2,3)4)18-15(23-12)11-13-7-9-14(10-8-13)19(20)21/h7-10H,11H2,1-6H3

description: dataset for 1H nuclear magnetic resonance spectroscopy (1H NMR) 1H NMR (62 MHz, CDCl3, ppm) δ = 8.17 (d, J = 8.8 Hz, 2H), 7.45 (d, J = 8.6 Hz, 2H), 4.21 (s, 2H), 2.17 (s, 3H), 0.97 (s, 9H), 0.22 (s, 6H).
DOI: 10.6084/m9.figshare.24495238
title: 4.Spatial distribution of the dominant drivers on vegetation growth across China over the past three decades

description: 4. Spatial distribution of the dominant drivers on vegetation growth across China over the past three decades<i>a. Spatial distributi</i><i>on of </i><i>the partial c</i><i>orrelation coefficient (Spearman)</i><i> between the </i><i>drivers </i><i>and </i><i>the Normalized Difference Vegetation Index (NDVI)/Leaf Area Index (LAI)/Gross Primary Productivity (GPP) across China over the 1982–2015 period</i>The drivers include air temperature (Tmp), precipitation (Pre), vapor pressure deficit (VPD), downward surface shortwave radiation (Rad), soil moisture (SM), and atmospheric carbon dioxide (CO<sub>2</sub>). We used the 25 10-year moving windows over the 1982–2015 period to reduce the uncertainty associated with inter-annual anomalies. We calculated the partial correlation coefficient (Spearman) for each grid cell for the 25 10-year moving windows. The factor with the highest absolute value of the significant partial correlation coefficient (two-tailed t-test: p &lt; 0.05) was identified as the dominant driver of changes in vegetation growth in that grid cell. You can use the "<b>China_vegetation_cover_map.tif</b>" in the dataset "1.Spatiotemporal patterns of vegetation growth across China over the past three decades" to extract the part of China.<i>b. The MATLAB (R2023a) code for calculating the partial correlation coefficient (Spearman) for each grid cell for the 25 10-year moving windows</i>This includes "<b>Partial_Correlation_Spearman.m</b>" for calculating the partial correlation coefficient (Spearman) for each grid cell for the 25 10-year moving windows and "<b>Random forest.m</b>" for building RF models to gauge the importance of climate and atmospheric CO<sub>2</sub> in driving changes in NDVI/LAI/GPP. We trained RF models pixel by pixel and then extracted the dominant driver for each grid cell by ranking the feature importance.
DOI: 10.6084/m9.figshare.24511975
title: Sample tweets from May 2022

description: Dataset containing twitter data, namely hashed twitter id, hashed user id, tweet language, user statistics.
DOI: 10.6084/m9.figshare.24511975.v2
title: Sample tweets from May 2022

description: Dataset containing twitter data, namely hashed twitter id, hashed user id, tweet language, user statistics.
DOI: 10.5519/qd.0wyjxuel
title: Query on the Natural History Museum Data Portal (data.nhm.ac.uk) (1 records)
DOI: 10.6084/m9.figshare.24042606.v1
title: Temperature mediates predation risk on invasive insects on a large tropical island

description: In tropical regions, insects face increased predation risks due to warmer temperatures and heightened ecological interactions. However, uncertainties remain in assessing predation risks in large tropical islands with diverse topography and high biological invasions. We conducted studies on Hainan Island, a vast tropical island, selecting 16 diverse locations to evaluate predation risk on the underground pupae of the invasive <i>Bactrocera dorsalis</i>. Findings show higher altitudes correlate with higher predation rates, while elevated temperatures negatively affect predation. This suggests temperature's crucial role in shaping predation risk and activity ranges of non-native insects and native predators, impacting predation and invasive prevalence in coastal regions. Moreover, we observed higher predation rates in organic soil. The study highlights the importance of temperature-induced ecological interactions in shaping insect predation risk, confirming the enemy release hypothesis, and raising concerns about global warming's impact on the expansion of invasive insect populations.
DOI: 10.6084/m9.figshare.23988061
title: Benefit finding, posttraumatic growth and health-related quality of life in long-term cancer survivors: a prospective population-based study

description: We explored the relationship between benefit finding (BF)/posttraumatic growth (PTG) at baseline and health-related quality of life (HRQOL) at baseline and follow-up in long-term cancer survivors (LTCS; ≥5-year post-diagnosis). HRQOL was assessed in LTCS in 2009–2011 (5- to 16-year post-diagnosis, baseline) and re-assessed in 2018/2019 (14- to 24-year post-diagnosis, follow-up). BF and PTG were measured at baseline; mean scores were dichotomized into ‘none-to-low’ (&lt;3) and ‘moderate-to-high’ (&gt; =3). Linear regression models and linear mixed regression models were employed to assess the association of BF/PTG with HRQOL. Of the 6057 baseline participants, 4373 were alive in 2019, of whom 2704 completed the follow-up questionnaire. Cross-sectionally, LTCS with none-to-low BF reported better HRQOL at baseline and at follow-up than LTCS with higher BF. Longitudinally, no difference was found between none-to-low and moderate-to-high BF on the HRQOL change from baseline to follow-up. HRQOL differences between the PTG groups were not statistically significant cross-sectionally and longitudinally, except those participants with moderate-to-high PTG reported higher role functioning and global health status/QOL. Cross-sectionally, BF was significantly negatively related to subscales of HRQOL, while PTG was positively correlated to role functioning and global health status/QOL. The results add further evidence that BF and PTG are two different positive psychological concepts.
DOI: 10.6084/m9.figshare.23988061.v1
title: Benefit finding, posttraumatic growth and health-related quality of life in long-term cancer survivors: a prospective population-based study

description: We explored the relationship between benefit finding (BF)/posttraumatic growth (PTG) at baseline and health-related quality of life (HRQOL) at baseline and follow-up in long-term cancer survivors (LTCS; ≥5-year post-diagnosis). HRQOL was assessed in LTCS in 2009–2011 (5- to 16-year post-diagnosis, baseline) and re-assessed in 2018/2019 (14- to 24-year post-diagnosis, follow-up). BF and PTG were measured at baseline; mean scores were dichotomized into ‘none-to-low’ (&lt;3) and ‘moderate-to-high’ (&gt; =3). Linear regression models and linear mixed regression models were employed to assess the association of BF/PTG with HRQOL. Of the 6057 baseline participants, 4373 were alive in 2019, of whom 2704 completed the follow-up questionnaire. Cross-sectionally, LTCS with none-to-low BF reported better HRQOL at baseline and at follow-up than LTCS with higher BF. Longitudinally, no difference was found between none-to-low and moderate-to-high BF on the HRQOL change from baseline to follow-up. HRQOL differences between the PTG groups were not statistically significant cross-sectionally and longitudinally, except those participants with moderate-to-high PTG reported higher role functioning and global health status/QOL. Cross-sectionally, BF was significantly negatively related to subscales of HRQOL, while PTG was positively correlated to role functioning and global health status/QOL. The results add further evidence that BF and PTG are two different positive psychological concepts.
DOI: 10.6084/m9.figshare.24163019
title: Impact of adjuvant chemotherapy on long-term overall survival in patients with high-risk stage II colon cancer: a nationwide cohort study

description: This study aimed to investigate the impact of adjuvant chemotherapy on long-term survival in unselected patients with high-risk stage II colon cancer including an analysis of each high-risk feature. Data from the Danish Colorectal Cancer Group, the National Patient Registry and the Danish Pathology Registry from 2014 to 2018 were merged. Patients surviving &gt; 90 days were included. High-risk features were defined as emergency presentation, including self-expanding metal stents (SEMS)/loop-ostomy as a bridge to resection, grade B or C anastomotic leakage, pT4 tumors, lymph node yield &lt; 12 or signet cell carcinoma. Eligibility criteria for chemotherapy were age &lt; 75 years, proficient MMR gene expression, and performance status ≤ 2. The primary outcome was 5-year overall survival. Secondary outcomes included the proportion of eligible patients allocated for adjuvant chemotherapy and the time to first administration. In total 939 of 3937 patients with stage II colon cancer had high-risk features, of whom 408 were eligible for chemotherapy. 201 (49.3%) patients received adjuvant chemotherapy, with a median time to first administration of 35 days after surgery. The crude 5-year overall survival was 84.9% in patients receiving adjuvant chemotherapy compared with 66.3% in patients not receiving chemotherapy, <i>p</i> &lt; 0.001. This association corresponded to an absolute risk difference of 14%. 5-year overall survival was significantly higher in patients with high-risk stage II colon cancer treated with adjuvant chemotherapy compared with no chemotherapy. Adjuvant treatment was given to less than half of the patients who were eligible for it.
DOI: 10.6084/m9.figshare.24163019.v1
title: Impact of adjuvant chemotherapy on long-term overall survival in patients with high-risk stage II colon cancer: a nationwide cohort study

description: This study aimed to investigate the impact of adjuvant chemotherapy on long-term survival in unselected patients with high-risk stage II colon cancer including an analysis of each high-risk feature. Data from the Danish Colorectal Cancer Group, the National Patient Registry and the Danish Pathology Registry from 2014 to 2018 were merged. Patients surviving &gt; 90 days were included. High-risk features were defined as emergency presentation, including self-expanding metal stents (SEMS)/loop-ostomy as a bridge to resection, grade B or C anastomotic leakage, pT4 tumors, lymph node yield &lt; 12 or signet cell carcinoma. Eligibility criteria for chemotherapy were age &lt; 75 years, proficient MMR gene expression, and performance status ≤ 2. The primary outcome was 5-year overall survival. Secondary outcomes included the proportion of eligible patients allocated for adjuvant chemotherapy and the time to first administration. In total 939 of 3937 patients with stage II colon cancer had high-risk features, of whom 408 were eligible for chemotherapy. 201 (49.3%) patients received adjuvant chemotherapy, with a median time to first administration of 35 days after surgery. The crude 5-year overall survival was 84.9% in patients receiving adjuvant chemotherapy compared with 66.3% in patients not receiving chemotherapy, <i>p</i> &lt; 0.001. This association corresponded to an absolute risk difference of 14%. 5-year overall survival was significantly higher in patients with high-risk stage II colon cancer treated with adjuvant chemotherapy compared with no chemotherapy. Adjuvant treatment was given to less than half of the patients who were eligible for it.